There Is a Lot of Fungus Among Us
The New York Times, April 24, 2021
Coffee for immune support. Supplements for inflammation. And psychedelics promising relief from serious ailments. Mushrooms are everywhere, and investors are paying attention.
Massachusetts General Hospital Launches Center to Study Neuroscience of Psychedelics
The Crimson, April 23, 2021
Massachusetts General Hospital, an affiliate of Harvard Medical School, launched a new center to study the clinical benefits of psychedelics in treating mental illness.
Psychedelics are transforming the way we understand depression and its treatment
The Guardian, April 20, 2021
Psychiatry has long failed to explain depression. Our research into psilocybin suggests a new approach could offer answers.
Psilocybin least as good as antidepressant in UK study
Reuters, April 15, 2021
A study published in the New England Journal of Medicine, psilocybin could be as effective as a leading antidepressant—and while more research is still required, the study’s lead author says the results should give people hope for functional alternatives to SSRIs.
New $6.4M research program to advance psychedelics research and treatments
Eurek Alert, March 30, 2021
Psychedelics research in support of brain health is getting a major boost this month with the formation of the Neuroscape Psychedelics Division at the University of California, San Francisco (UCSF).
Suing the DEA for Access to Psilocybin
Mushroom Revival, March 24, 2021
A Seattle based doctor, Dr. Sunil Aggarwal, has filed a lawsuit against the DEA for denying him permission to use psilocybin therapy in his palliative care.
Psychedelic for meth users: Sydney trial aims to conquer addiction
Sydney Morning Herald, March 22, 2021
A world-first clinical trial in Sydney aims to find out if giving psychedelics to people who use methamphetamines can help conquer their addiction.
Researchers at St Vincent’s Hospital in Darlinghurst will use psilocybin to turbocharge therapy for patients dependent on “meth” or “ice”.
Can Magic Mushrooms Heal Us?
The New York Times, March 18, 2021
A very promising mental health experiment is taking shape in Oregon.
Australian Government to Spend $15m on Psychedelic Trials
Vice, March 17, 2021
The Australian government will fund a series of clinical trials into the potential use of psilocybin, MDMA, ketamine and other drugs as treatments for debilitating mental illnesses. The $15 million Innovative Therapies for Mental Illness Grant Opportunity aims to bolster Australian-led research into drug and psychedelic-assisted psychotherapy.
‘Better treatments’: Government to fund psychedelic drugs trials to treat mental illness
Sydney Morning Herald, March 17, 2021
Clinical trials using magic mushrooms, ecstasy and other psychedelic drugs in potential breakthrough therapies for debilitating mental illnesses will be funded by the Australian federal government as part of global efforts to advance innovative treatments. The Morrison government launched a $15 million competitive grant round to kick-start Australian clinical trials of potential breakthrough combination therapies.
Psychedelic therapy could ‘reset’ depressed brain
BBC News, March 16, 2021
A powerful hallucinogenic medicine known for its part in shamanic rituals is being trialled as a potential cure for depression for the first time.
Creso Pharma Acquisition of Psychedelic Company Halucenex Life Sciences Inc.
Vancouver Sun, March 15, 2021
Creso Pharma has announced a transformational move to evolve from a medical cannabis company to an integrated natural medicines provider with the acquisition of Canadian psychedelics company, Halucenex Life Sciences Inc.
New Legion Veterans Village in Surrey will include centre to research medical psychedelics
Small Caps, March 13, 2021
Surrey will soon be home to a research centre that brings together experts in medical cannabis and psychedelics to help people with post-traumatic stress disorder.
Suicide warning over denied drugs
The Australian, March 9, 2021
Delaying mental practitioners access to psilocybin and MDMA could result in a spike in suicides amid an ongoing national mental health crisis, according to advocates for psychedelic-assisted therapy.
How psilocybin eased my cancer suffering
Herald Sun, March 9, 2021
Follows the story of Candian, Thomas Hartle, who has utilized psilocybin therapies to ease the suffering and pain from his stage 4 colon cancer.
NYU is Launching a Center for Psychedelic Medicine
Freethink, March 7, 2021
NYU’s Langone Health joins the research renaissance.
Greens MP hopes Canberra will be the first to introduce psychedelic assisted therapy
The Canberra Times, March 7, 2021
ACT Greens’ MLA Johnathan Davis wants Canberra to be the first jurisdiction to provide an accessible path for psychiatrists to prescribe psychedelic-assisted therapy to patients experiencing serious mental concerns.
Study Reveals More People are Using Psychedelics to Self-Treat Mental Health
Vice, March 5, 2021
The use of psychedelic medicines as an underground self-treatment for mental health conditions is on the rise, according to the world’s largest drug survey, with thousands of people turning to substances like LSD, MDMA, psilocybin and ketamine to treat psychiatric illnesses and emotional distress.
Why the TGA should down-schedule psilocybin and MDMA
Honi Soit, February 26, 2021
The Therapeutic Goods Administration should lead the way in destigmatising psychedelics.
Demand for illegal drugs in therapy
The Australian, February 21, 2021
After an interim decision by the health regulator rejected an application to make psilocybin and MDMA more accessible for psychiatrists to treat mental illness, patients are increasingly turning to illicit treatments.